CD169+ lymph node macrophages have protective functions in mouse breast cancer metastasis
Carlotta Tacconi,
Catharina D. Commerford,
Lothar C. Dieterich,
Simon Schwager,
Yuliang He,
Kristian Ikenberg,
Ekaterina Friebel,
Burkhard Becher,
Sònia Tugues,
Michael Detmar
Affiliations
Carlotta Tacconi
Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
Catharina D. Commerford
Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
Lothar C. Dieterich
Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
Simon Schwager
Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
Yuliang He
Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
Kristian Ikenberg
Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland; Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
Ekaterina Friebel
Department of Experimental Immunology, University of Zurich, Zurich, Switzerland
Burkhard Becher
Department of Experimental Immunology, University of Zurich, Zurich, Switzerland
Sònia Tugues
Department of Experimental Immunology, University of Zurich, Zurich, Switzerland; Corresponding author
Michael Detmar
Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland; Corresponding author
Summary: Although the contribution of macrophages to metastasis is widely studied in primary tumors, the involvement of macrophages in tumor-draining lymph nodes (LNs) in this process is less clear. We find CD169+ macrophages as the predominant macrophage subtype in naive LNs, which undergo proliferative expansion in response to tumor stimuli. CD169+ LN macrophage depletion, using an anti-CSF-1R antibody or clodronate-loaded liposomes, leads to increased metastatic burden in two mouse breast cancer models. The expansion of CD169+ macrophages is tightly connected to B cell expansion in tumor-draining LNs, and B cell depletion abrogates the effect of CD169+ macrophage absence on metastasis, indicating that the CD169+ macrophage anti-metastatic effects require B cell presence. These results reveal a protective role of CD169+ LN macrophages in breast cancer metastasis and raise caution for the use of drugs aiming at the depletion of tumor-associated macrophages, which might simultaneously deplete macrophages in tumor-draining LNs.